SCHEMBL2431769

SCHEMBL2431769

N#Cc1cccc(-c2cc(Br)c3cnccc3c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.51
CHRNA5 P30532 2/20 0.51
CHRNA4 P43681 2/20 0.51
CYP11B1 P15538 2/20 0.48
CYP11B2 P19099 2/20 0.48
CYP17A1 P05093 1/20 0.48
CLK4 Q9HAZ1 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.43
NEK1 Q96PY6 1/20 0.43
IDO1 P14902 2/20 0.43
GRM5 P41594 1/20 0.42
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
USP2 O75604 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13089949 0.84 CYP17A1 (0.48) CHRNB2CHRNA5CHRNA4CYP11B1CYP11B2
SCHEMBL12327914 0.84 CYP11B1 (0.48) CHRNB2CHRNA5CHRNA4CYP11B1CYP11B2
SCHEMBL15172419 0.81 CYP11B1 (0.45) CHRNB2CHRNA5CHRNA4CYP11B1CYP11B2
SCHEMBL15172398 0.79 CYP11B2 (0.66) CHRNB2CHRNA5CHRNA4CYP11B1CYP11B2
SCHEMBL3713151 0.78 MAPK10 (0.48) CYP11B1CYP11B2CYP17A1NCOA3HPGD
SCHEMBL13090021 0.76 HTR6 (0.51) CHRNB2CHRNA5CHRNA4CYP11B1CYP11B2
SCHEMBL13087407 0.75 HRH3 (0.39) CHRNB2CHRNA5CHRNA4CYP11B1CYP11B2
SCHEMBL2424122 0.75 IKBKB (0.45) CHRNB2CHRNA5CHRNA4CYP11B1CYP11B2
SCHEMBL3721376 0.75 GRM5 (0.40) CYP11B1CYP11B2CYP17A1GRM5CYP1A2
SCHEMBL3630922 0.74 SLC6A4 (0.41) CHRNB2CHRNA5CHRNA4CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102171204-B 8-substituted isoquinoline derivative and application thereof ASAHI KASEI PHARMA CORP 2014-08-20 CN disclosed
EP-2366699-B1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2013-08-07 EP disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
EP-2366699-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2011-09-21 EP disclosed
CN-102171204-A 8-substituted isoquinoline derivative and application thereof ASAHI KASEI PHARMA CORP 2011-08-31 CN disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 CHRNB2 3479/4885CHRNA5 2916/4885CHRNA4 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.